An interventional study of Online Survey in Diabetic Retinopathy, sponsored by University of Wisconsin, Madison. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Health services research
Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 56 under way, 6 of them phase 3. Diabetic Retinopathy · United States.
Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 11th largest by enrollment of the 196 interventional ones, is one of 12 that started in 2025, is one of 53 with no phase, and was the 229th registered.
778 studies on the registry are indexed under Diabetic Retinopathy; 142 are open to participants now.
This study's enrollment of 1,811 is above the median of 80 across 481 interventional studies indexed under Diabetic Retinopathy.
Browse Diabetic Retinopathy studies →36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →267 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 12 started in 2025.
Median enrollment 72 across the 196 interventional studies, 161 across the 70 observational. Of the 186 that completed or were terminated, 66 (35%) have results posted.
114 of 267 have an industry lead sponsor. The 10 most frequent:
University of Wisconsin, Madison is the lead sponsor of 1,188 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
University of Wisconsin, Madison has 7 studies filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
19 of the studies in Diabetic Retinopathy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07235085Phase 3Ocular Therapeutix, Inc.A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | 2027-03 |
| NCT06191094University of Colorado, DenverPre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy | 2026-12 |
| NCT04008121MediBeaconFeasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium | 2026-12 |
| NCT07891910Retina Consultants of DelmarvaIopidine to Decrease Intraocular Pressure Rise After Injections | 2026-12-01 |
| NCT05463289Johns Hopkins UniversityACCESS 2: AI for pediatriC diabetiC Eye examS Study 2 | 2026-12-30 |
Among the 267 studies in Diabetic Retinopathy with a site in United States, from their registry updates:
An online survey (n=1,500) and 4 focus groups will be conducted with Latinx patients with diabetes (n=20) to obtain preliminary data regarding whether and how patient and clinician video testimonial interventions (n=6) increase eye health literacy and trust in healthcare.
3 Latinx patients with diabetes and 3 Latinx clinicians will be recruited to videotape testimonials regarding the importance of diabetic eye screening and teleophthalmology use from their personal experiences. The investigators will structure the testimonials as a series of responses to a brief set of interview questions, or prompts, designed to elicit key messages previously identified by our community stakeholders as being particularly important, based on our prior studies and those of others and conducted in Spanish (with English subtitles).
After the Latinx patient and clinician video testimonials are recorded, a community outreach specialist bilingual in Spanish and English will facilitate a series of 4 community stakeholder meetings (90 min. each) to develop the culturally-adapted, video-based patient education intervention to increase diabetic eye screening and teleophthalmology use among Latinos.
After patient education videos are developed, an online survey will be conducted (n=1500) to test 3 versions of the video-based patient education intervention: (1) patient + clinician combined testimonials, (2) patient testimonials only, (3) clinician testimonials only, and compare them to 2 control conditions: (1) a standard educational video, publicly available online from the National Eye Institute, and (2) pre-video questionnaire-only control in a mixed-effects randomized design with pre- and post-measures (video conditions treated as the between-subjects factor).
Finally, a community outreach specialist bilingual in Spanish and English will facilitate focus groups (60-90 minutes) in the participants' preferred language (participants will be grouped based on their preference for either Spanish or English). Focus groups will begin by having each participant complete a brief survey instrument that will be read aloud and adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale). Participants will then silently view the video-based, patient education intervention (patient + clinician combined version). Afterwards, they will complete the same brief survey instrument to obtain a pre-/post-comparison of any differences in their responses that may result from viewing the video intervention.
Together with the online survey results, the investigators will test the intervention's ability to increase eye health literacy and trust in healthcare for obtaining eye care.
Inclusion Criteria (online survey participants):
Inclusion Criteria (patient video testimonials):
Inclusion Criteria (clinician video testimonials):
Inclusion Criteria (focus group participants):
Exclusion Criteria:
-
In addition to being randomized for online survey participants, focus groups will view patient plus clinician combined testimonials.
Other: Online Survey
Other: Online Survey
Other: Online Survey
Other: Online Survey
Other: Online Survey
Participants must self-identify as Latinx adults and complete a brief online survey adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale) both before and after viewing the video-based, patient education intervention to obtain a pre to post-comparison of any differences in their responses.
Change in Eye Health Literacy as measured by Compliance with Annual Diabetic Eye Exams Survey (CADEES)
CADEES is scored from 1-5 where higher scores indicate increase eye health literacy.
Time frame: pre and post video testimonial intervention (up to 90 minutes)
Change in Trust in Healthcare as measured by Trust in the Health Care Team (T-HCT) scale score
T-HCT is scored from 1-5 where higher scores indicate increased trust in healthcare.
Time frame: pre and post video testimonial intervention (up to 90 minutes)
Plan to share: Yes — De-identified data regarding patient demographics, whether they obtained diabetic eye screening, had teleophthalmology performed, any vision-threatening eye condition identified by teleophthalmology, and whether they followed-up for in-person eye care if they screened positive will be available to share.
Supporting information: Study protocol, Statistical analysis plan
Time frame: up to 7 years after the completion of the primary outcome
Access criteria: contact study PI for access
Ran from May 2025 to primary completion in Oct 2026, 16 months.
Of 111 non-industry interventional studies with no phase under Diabetic Retinopathy, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's 16 months is below that.
Counting every sponsor, half of 126 studies reached it within 29 months; a quarter within 11 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Wisconsin, Madison →